14-day Premium Trial Subscription Try For FreeTry Free

Allogene Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 96.37. In total, the insiders bought 22 434 320 and sold 304 156 ALLO shares in the last 100 trades.

Insider Power

(Last 100 transactions)
96.37
Buy 22 434 320 Shares
Sell 304 156 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 18, 2024 Common Stock Sell Messemer Deborah M. 18 641
Jun 05, 2024 Common Stock Buy Yoshiyama Annie 0
Jun 05, 2024 Stock Option (Right to buy) Buy Yoshiyama Annie 348 708
Jun 05, 2024 Stock Option (Right to buy) Buy Mayo Stephen 191 082
Jun 05, 2024 Stock Option (Right to buy) Buy Barrett Elizabeth A. 191 082
Jun 05, 2024 Common Stock Buy Sato Vicki L 61 475
Jun 05, 2024 Stock Option (Right to buy) Buy Sato Vicki L 95 541
Jun 05, 2024 Common Stock Buy Humer Franz B 61 475
Jun 05, 2024 Stock Option (Right to buy) Buy Humer Franz B 95 541
Jun 05, 2024 Stock Option (Right to buy) Buy Witte Owen N. 191 082
Jun 05, 2024 Stock Option (Right to buy) Buy Kazam Joshua A 191 082
Jun 05, 2024 Common Stock Buy Messemer Deborah M. 122 950
May 30, 2024 Common Stock Sell Humer Franz B 11 200
May 16, 2024 Common Stock Buy Belldegrun Arie 1 724 137
May 16, 2024 Common Stock Buy Belldegrun Arie 344 828
May 16, 2024 Common Stock Buy Parker Geoffrey M. 344 828
May 16, 2024 Common Stock Buy Chang David D 344 828
Apr 22, 2024 Common Stock Sell Moore Timothy L. 17 360
Mar 14, 2024 Common Stock Sell Chang David D 53 393
Jan 30, 2024 Common Stock Buy Parker Geoffrey M. 190
Jan 25, 2024 Stock Option (Right to buy) Buy Moore Timothy L. 341 515
Jan 25, 2024 Common Stock Buy Moore Timothy L. 96 600
Jan 25, 2024 Common Stock Buy Douglas Earl Martin 41 800
Jan 25, 2024 Stock Option (Right to buy) Buy Douglas Earl Martin 147 778
Jan 25, 2024 Common Stock Buy Parker Geoffrey M. 29 400
Click to get the best stock tips daily for free!

About Allogene Therapeutics Inc.

Allogene Therapeutics Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ... ALLO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT